MENU
+Compare
HRMY
Stock ticker: NASDAQ
AS OF
Jun 2, 04:59 PM (EDT)
Price
$35.60
Change
+$1.10 (+3.19%)
Capitalization
1.98B

HRMY Harmony Biosciences Holdings Forecast, Technical & Fundamental Analysis

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs... Show more

HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HRMY with price predictions
May 30, 2025

Aroon Indicator for HRMY shows an upward move is likely

HRMY's Aroon Indicator triggered a bullish signal on May 30, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 179 similar instances where the Aroon Indicator showed a similar pattern. In of the 179 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on HRMY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

HRMY moved above its 50-day moving average on May 06, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HRMY crossed bullishly above the 50-day moving average on May 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HRMY moved out of overbought territory on May 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on May 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRMY broke above its upper Bollinger Band on May 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.834) is normal, around the industry mean (16.282). P/E Ratio (13.573) is within average values for comparable stocks, (59.459). HRMY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (2.774) is also within normal values, averaging (270.467).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

HRMY is expected to report earnings to fall 29.70% to 72 cents per share on August 12

Harmony Biosciences Holdings HRMY Stock Earnings Reports
Q2'25
Est.
$0.72
Q1'25
Beat
by $0.42
Q4'24
Beat
by $0.39
Q3'24
Beat
by $0.12
Q2'24
Beat
by $1.04
The last earnings report on May 06 showed earnings per share of $1.03, beating the estimate of 61 cents. With 673.38K shares outstanding, the current market capitalization sits at 1.98B.
A.I. Advisor
published General Information

General Information

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
630 West Germantown Pike
Phone
+1 484 539-9800
Employees
246
Web
https://www.harmonybiosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JICPX15.470.04
+0.26%
JHFunds2 Capital Appreciation 1
FWWFX34.240.01
+0.03%
Fidelity Worldwide
ANFFX62.91-0.05
-0.08%
American Funds New Economy F1
ABMIX22.15-0.04
-0.18%
AMG River Road Mid Cap Value I
LMVVX26.22-0.22
-0.83%
Lord Abbett Focused Small Cap Value R5

HRMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+1.32%
SNBIF - HRMY
52%
Loosely correlated
N/A
SAGE - HRMY
41%
Loosely correlated
-0.92%
CYTK - HRMY
37%
Loosely correlated
-0.96%
GLYC - HRMY
35%
Loosely correlated
-1.55%
ANAB - HRMY
35%
Loosely correlated
-1.46%
More